REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Autoimmune Modulation

Immune Supportadvanced

77

synergy

77
Share
Peptides

3

Avg Daily mcg

2,400

Level

advanced

Added

May 17, 2026

Overview

The Autoimmune Modulation stack represents an experimental approach to immune rebalancing for individuals with autoimmune conditions, focusing on reducing pathological inflammation while preserving immune competence. KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains alpha-MSH''s potent anti-inflammatory properties while lacking its melanogenic (skin-darkening) effects. KPV inhibits NF-kB nuclear translocation — the master switch for inflammatory gene transcription — and reduces production of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta. In animal models of inflammatory bowel disease, KPV demonstrated significant reduction in mucosal inflammation and disease activity. BPC-157 at the higher 500mcg oral dose targets the gastrointestinal tract directly, where many autoimmune conditions have their origins or maintenance mechanisms. The gut-associated lymphoid tissue (GALT) is the largest immune organ, and intestinal permeability ("leaky gut") is now recognized as a contributing factor in multiple autoimmune diseases including celiac disease, rheumatoid arthritis, type 1 diabetes, and inflammatory bowel disease. BPC-157''s ability to restore mucosal integrity and modulate local immune responses addresses this fundamental mechanism. Thymosin Alpha-1 is included not for immune stimulation per se, but for immune modulation — it helps restore the regulatory T-cell (Treg) populations that are often depleted in autoimmune conditions. Tregs are the "brakes" of the immune system, preventing overactivation and self-directed attacks. Ta1 promotes thymic output of naive T-cells that can differentiate into Tregs under appropriate conditions. The advanced classification reflects the complexity of autoimmune conditions and the absolute necessity of physician supervision. This stack should complement, never replace, prescribed immunomodulatory therapy. It is most appropriate for individuals in remission seeking to support ongoing immune balance.

Dosing Protocol

KPV

Twice per day· oral or subcutaneous

Read more about KPV →

200 mcg

per dose

BPC-157

Every day· oral

Read more about BPC-157 →

500 mcg

per dose

Thymosin Alpha-1

2x/week· subcutaneous

Read more about Thymosin Alpha-1 →

1,500 mcg

per dose

Goals & Evidence

Autoimmune modulationInflammationGut inflammationImmune balanceTNF reduction
Evidence tier:Animal Studies

Warnings

  • KPV (alpha-MSH fragment) has limited human data but promising anti-inflammatory research. This is an experimental immunomodulatory protocol. Do NOT replace prescribed immunosuppressants.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.